Thymosin Alpha-1Healing & Recovery
Immune-modulating peptide studied for resilience.
- Status
- Research / not approved
- Developer
- Isolated by Allan Goldstein (1970s); thymalfasin / Zadaxin (SciClone)
- Receptors / target
- Immunomodulator; agonist of TLR2 and TLR9 on dendritic cells, promoting dendritic-cell activation and maturation of CD4+/CD8+ T cells
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- immune modulationchronic hepatitis B & C (adjunct)vaccine adjuvantsepsis & severe infection
Overview
Thymosin alpha-1 (Tα1; INN thymalfasin; brand Zadaxin) is a 28-amino-acid immunomodulatory peptide derived from prothymosin alpha. A synthetic version is approved and marketed in 35+ countries — primarily for chronic hepatitis B and C and as an immune enhancer/vaccine adjuvant — but it is not FDA-approved in the United States, where it has held only orphan-drug designations. In the US it is handled as a research-use-only compound; nothing here is medical or dosing advice.
Mechanism
Tα1 acts as an agonist of Toll-like receptors TLR2 and TLR9 on dendritic cells, triggering their activation and maturation, which in turn promotes maturation of T-cell progenitors into CD4+ and CD8+ subsets and helps normalize T-lymphocyte function — a broad immunomodulator rather than a direct antiviral. In states of immune exhaustion, human data show it can lower exhaustion markers (PD-1, Tim-3) on CD8+ T cells.
Clinical evidence
Human evidence is substantial relative to most research peptides. In severe sepsis, the multicenter randomized ETASS trial (361 patients) found lower in-hospital mortality with Tα1 (28.7% vs 39.4%), and a meta-analysis of 19 RCTs (1,354 patients) reported reduced 28-day mortality. In chronic hepatitis B, a meta-analysis of 4 RCTs found higher sustained virological response than interferon alpha at 6 months. COVID-19 data are limited to retrospective observational cohorts and should be read with caution given the lack of randomization. Much of the RCT evidence originates from China and varies in quality.
Safety profile
Across the sepsis RCT literature, thymosin alpha-1 was well tolerated: the 19-RCT meta-analysis reported no Tα1-related severe adverse events and no discontinuations for intolerance. Pharmacokinetics show a short elimination half-life (under ~3 hours) after subcutaneous injection with no accumulation. As a YMYL caveat: most efficacy trials enrolled hospitalized patients with serious illness, and the US regulatory status means there is no FDA-vetted safety labeling — material limitations to weigh.
- Weeks
In its approved-abroad uses (hepatitis B/C, sepsis adjunct), immune effects and outcomes are assessed over weeks-long courses.
- Note
Not FDA-approved in the US; 'immune boosting' in healthy people has no defined time-course and is unproven.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions (erythema, discomfort)
- Transient fatigue
- Mild flu-like symptoms
- Generally well tolerated in trials
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No FDA-approved US labeling exists, so there is no vetted contraindication list; the following are precautionary.
- Known hypersensitivity to thymalfasin or formulation components
- Use during immunosuppressive therapy or after organ transplantation should be supervised, given its T-cell-activating mechanism
- Pregnancy and breastfeeding: human safety data are absent
- No documented clinically significant human drug interactionsInteraction profile uncharacterized; theoretical opposition to immunosuppressants given its immune-activating mechanism (research use only)
Compare
- vs LL-37
Both are immune-active peptides, but LL-37 is a host-defense cathelicidin with a double-edged, partly pro-inflammatory and cytotoxic profile, while Ta1 is a better-tolerated T-cell-maturation immunomodulator with far more human trial data.
FAQ
Is thymosin alpha-1 approved by the FDA?
No. A synthetic version (thymalfasin, brand Zadaxin) is approved and marketed in 35+ countries for chronic hepatitis B/C and as an immune adjuvant, but it is not FDA-approved in the United States, where it has held only orphan-drug designations and is handled as research-use only.
What does thymosin alpha-1 do?
It is an immunomodulator that acts as an agonist of TLR2 and TLR9 on dendritic cells, promoting their activation and the maturation of CD4+ and CD8+ T cells. It helps normalize T-cell function rather than acting as a direct antiviral.
Is the human evidence strong?
Relative to most research peptides, yes: a multicenter sepsis RCT (ETASS) and meta-analyses in sepsis and hepatitis B show benefit. But much of the RCT evidence originates from China and varies in quality, COVID-19 data are only retrospective, and there is no FDA-vetted safety labeling.
How is thymosin alpha-1 (Zadaxin) administered and dosed?
In its approved-abroad uses it is given by subcutaneous injection. A commonly cited regimen is 1.6 mg twice weekly over a multi-week course for hepatitis or as an immune adjuvant. This is context from the thymalfasin/Zadaxin label, not US-approved dosing or medical advice.
Is thymosin alpha-1 well tolerated?
In the sepsis RCT literature it was well tolerated — the 19-RCT meta-analysis reported no Tα1-related severe adverse events and no discontinuations for intolerance. The most common complaints are injection-site reactions, transient fatigue and mild flu-like symptoms. Note that most efficacy trials enrolled hospitalized, seriously ill patients.
Can thymosin alpha-1 'boost immunity' in healthy people?
There is no controlled evidence for general 'immune boosting' in healthy individuals; the human trials studied specific conditions such as sepsis and chronic hepatitis. Because it activates T cells, use alongside immunosuppressive therapy or after organ transplantation should be medically supervised. Research-use only in the US.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.